Restricted Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Pediatric B-Lineage Acute Lymphoblastic Leukemia Suggests Targetability with Therapeutic Monoclonal Antibodies

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Dave, Hema ^a   Anver, Miriam R ^b   Butcher, Donna O ^b   Brown, Patrick ^c   Khan, Javed ^a   Wayne, Alan S ^a   Baskar, Sivasubramanian ^a   Rader, Christoph ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN ROR1; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; B CELL LEUKEMIA; BLAST CELL; CELL SURFACE; CHILD; CONTROLLED STUDY; CYTOGENETICS; DIPLOIDY; DRUG TARGETING; FLOW CYTOMETRY; GENE REARRANGEMENT; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; KARYOTYPE; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; WESTERN BLOTTING;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOPHENOTYPING; INFANT; MALE; MOLECULAR TARGETED THERAPY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; RNA, MESSENGER; YOUNG ADULT;

EID: 84871429839     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052655     Document Type: Article

References (36)

1. Carroll WL, Bhojwani D, Min DJ, Raetz E, Relling M, et al. (2003) Pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program: 102-131.
2. Pui CH, Relling MV, Downing JR, (2004) Acute lymphoblastic leukemia. N Engl J Med 350: 1535-1548.
3. Barth M, Raetz E, Cairo MS, (2012) The future role of monoclonal antibody therapy in childhood acute leukaemias. Br J Haematol 159: 3-17.
4. Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, et al. (2008) Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol 26: 3756-3762.
5. Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK, (2007) Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 21: 2240-2245.
6. de Vries JF, Zwaan CM, De Bie M, Voerman JS, den Boer ML, et al. (2011) The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia.
7. Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, et al. (2010) Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res 16: 1894-1903.
8. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, et al. (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29: 2493-2498.
9. Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, et al. (2011) Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 25: 181-184.
10. Masiakowski P, Carroll RD, (1992) A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem 267: 26181-26190.
11. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, et al. (2001) Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194: 1625-1638.
12. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, et al. (2001) Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194: 1639-1647.
13. Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, et al. (2008) Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res 14: 396-404.
14. Fukuda T, Chen L, Endo T, Tang L, Lu D, et al. (2008) Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci U S A 105: 3047-3052.
15. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, Bayat AA, Ghods R, et al. (2008) Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer 123: 1190-1195.
16. Barna G, Mihalik R, Timar B, Tombol J, Csende Z, et al. (2011) ROR1 expression is not a unique marker of CLL. Hematol Oncol 29: 17-21.
17. Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, et al. (2010) The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood 116: 4532-4541.
18. Broome HE, Rassenti LZ, Wang HY, Meyer LM, Kipps TJ, (2011) ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk Res 35: 1390-1394.
19. Shabani M, Asgarian-Omran H, Vossough P, Sharifian RA, Faranoush M, et al. (2008) Expression profile of orphan receptor tyrosine kinase (ROR1) and Wilms' tumor gene 1 (WT1) in different subsets of B-cell acute lymphoblastic leukemia. Leuk Lymphoma 49: 1360-1367.
20. Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, et al. (2009) RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A 106: 8695-8700.
21. Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, et al. (2003) Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 102: 2951-2959.
22. Zhang S, Chen L, Cui B, Chuang HY, Yu J, et al. (2012) ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One 7: e31127.
23. Ariffin H, Chen SP, Wong HL, Yeoh A, (2003) Validation of a multiplex RT-PCR assay for screening significant oncogene fusion transcripts in children with acute lymphoblastic leukaemia. Singapore Med J 44: 517-520.
24. Sanchez-Solana B, Laborda J, Baladron V, (2012) Mouse resistin modulates adipogenesis and glucose uptake in 3T3-L1 preadipocytes through the ROR1 receptor. Mol Endocrinol 26: 110-127.
25. Yang J, Baskar S, Kwong KY, Kennedy MG, Wiestner A, et al. (2011) Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. PLoS One 6: e21018.
26. Baskar S, Wiestner A, Wilson WH, Pastan I, Rader C, (2012) Targeting malignant B cells with an immunotoxin against ROR1. mAbs 4: 349-361.
27. Crist WM, Carroll AJ, Shuster JJ, Behm FG, Whitehead M, et al. (1990) Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood 76: 117-122.
28. Oishi I, Takeuchi S, Hashimoto R, Nagabukuro A, Ueda T, et al. (1999) Spatio-temporally regulated expression of receptor tyrosine kinases, mRor1, mRor2, during mouse development: implications in development and function of the nervous system. Genes Cells 4: 41-56.
29. Al-Shawi R, Ashton SV, Underwood C, Simons JP, (2001) Expression of the Ror1 and Ror2 receptor tyrosine kinase genes during mouse development. Dev Genes Evol 211: 161-171.
30. Gashaw I (2011) What makes a good drug target? Drug Discovery Today 00.
31. MacKeigan JP, Murphy LO, Blenis J, (2005) Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 7: 591-600.
32. Yamaguchi T, Yanagisawa K, Sugiyama R, Hosono Y, Shimada Y, et al. (2012) NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 21: 348-361.
33. Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM, (2011) Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res 71: 3132-3141.
34. Rebagay G, Yan S, Liu C, Cheung NK, (2012) ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy. Front Oncol 2: 34.
35. Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, et al. (2010) Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 115: 2619-2629.
36. Zhou M, Zaki SR, Ragab AH, Findley HW, (1994) Characterization of a myeloperoxidase mRNA(+) acute lymphoblastic leukemia cell line (EU-1/ALL) established from a child with an apparent case of ALL. Leukemia 8: 659-663.